G1 Therapeutics Inc
NASDAQ:GTHX
Income Statement
Earnings Waterfall
G1 Therapeutics Inc
Revenue
|
82.5m
USD
|
Cost of Revenue
|
-7.2m
USD
|
Gross Profit
|
75.3m
USD
|
Operating Expenses
|
-114.8m
USD
|
Operating Income
|
-39.5m
USD
|
Other Expenses
|
-8.4m
USD
|
Net Income
|
-48m
USD
|
Income Statement
G1 Therapeutics Inc
Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
29
+1 243%
|
45
+58%
|
60
+31%
|
64
+7%
|
42
-34%
|
31
-25%
|
24
-23%
|
28
+16%
|
47
+67%
|
51
+9%
|
57
+12%
|
89
+55%
|
78
-13%
|
83
+6%
|
|
Gross Profit | ||||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(7)
|
(7)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
14
N/A
|
20
+41%
|
24
+22%
|
29
+22%
|
22
-26%
|
26
+17%
|
44
+71%
|
48
+9%
|
53
+11%
|
84
+59%
|
71
-16%
|
75
+6%
|
|
Operating Income | ||||||||||||||||||||||||||||||
Operating Expenses |
(30)
|
(37)
|
(45)
|
(54)
|
(61)
|
(69)
|
(76)
|
(80)
|
(89)
|
(94)
|
(105)
|
(119)
|
(129)
|
(135)
|
(135)
|
(138)
|
(142)
|
(149)
|
(160)
|
(170)
|
(172)
|
(185)
|
(188)
|
(187)
|
(184)
|
(168)
|
(151)
|
(132)
|
(115)
|
|
Selling, General & Administrative |
(5)
|
(4)
|
(5)
|
(6)
|
(7)
|
(9)
|
(11)
|
(14)
|
(19)
|
(23)
|
(29)
|
(35)
|
(41)
|
(44)
|
(49)
|
(57)
|
(69)
|
(80)
|
(91)
|
(97)
|
(96)
|
(99)
|
(100)
|
(100)
|
(101)
|
(95)
|
(87)
|
(80)
|
(72)
|
|
Research & Development |
(25)
|
(32)
|
(40)
|
(48)
|
(54)
|
(60)
|
(65)
|
(67)
|
(71)
|
(71)
|
(76)
|
(83)
|
(88)
|
(91)
|
(86)
|
(81)
|
(72)
|
(69)
|
(70)
|
(73)
|
(75)
|
(86)
|
(88)
|
(87)
|
(83)
|
(72)
|
(64)
|
(53)
|
(43)
|
|
Operating Income |
(30)
N/A
|
(37)
-21%
|
(45)
-22%
|
(54)
-21%
|
(61)
-13%
|
(69)
-14%
|
(76)
-9%
|
(80)
-6%
|
(89)
-11%
|
(94)
-6%
|
(105)
-12%
|
(119)
-13%
|
(129)
-9%
|
(135)
-5%
|
(133)
+1%
|
(109)
+18%
|
(96)
+11%
|
(90)
+7%
|
(98)
-8%
|
(129)
-32%
|
(142)
-10%
|
(164)
-15%
|
(162)
+1%
|
(143)
+12%
|
(136)
+5%
|
(115)
+15%
|
(67)
+42%
|
(61)
+8%
|
(40)
+36%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(5)
|
(6)
|
(8)
|
(9)
|
(10)
|
(10)
|
(10)
|
(8)
|
(8)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
4
|
6
|
7
|
7
|
7
|
5
|
3
|
1
|
(1)
|
(1)
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(0)
|
0
|
1
|
1
|
2
|
2
|
|
Pre-Tax Income |
(30)
N/A
|
(37)
-21%
|
(45)
-21%
|
(54)
-20%
|
(60)
-12%
|
(68)
-13%
|
(74)
-8%
|
(78)
-6%
|
(85)
-9%
|
(89)
-4%
|
(99)
-11%
|
(111)
-13%
|
(122)
-10%
|
(130)
-6%
|
(130)
0%
|
(108)
+17%
|
(98)
+10%
|
(93)
+5%
|
(101)
-9%
|
(133)
-31%
|
(147)
-11%
|
(170)
-16%
|
(171)
0%
|
(152)
+11%
|
(146)
+4%
|
(124)
+15%
|
(75)
+40%
|
(68)
+9%
|
(45)
+34%
|
|
Net Income | ||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
|
Income from Continuing Operations |
(30)
|
(37)
|
(45)
|
(54)
|
(60)
|
(68)
|
(74)
|
(78)
|
(85)
|
(89)
|
(99)
|
(111)
|
(122)
|
(130)
|
(130)
|
(109)
|
(99)
|
(95)
|
(103)
|
(134)
|
(148)
|
(171)
|
(171)
|
(154)
|
(148)
|
(126)
|
(78)
|
(71)
|
(48)
|
|
Net Income (Common) |
(35)
N/A
|
(45)
-28%
|
(52)
-16%
|
(60)
-15%
|
(65)
-9%
|
(68)
-6%
|
(74)
-8%
|
(78)
-6%
|
(85)
-9%
|
(89)
-4%
|
(99)
-11%
|
(111)
-13%
|
(122)
-10%
|
(130)
-6%
|
(130)
0%
|
(109)
+16%
|
(99)
+9%
|
(95)
+5%
|
(103)
-9%
|
(134)
-30%
|
(148)
-11%
|
(171)
-15%
|
(171)
0%
|
(154)
+10%
|
(148)
+4%
|
(126)
+15%
|
(78)
+38%
|
(71)
+9%
|
(48)
+32%
|
|
EPS (Diluted) |
-1.27
N/A
|
-1.62
-28%
|
-1.87
-15%
|
-2.1
-12%
|
-3.57
-70%
|
-2.33
+35%
|
-2.25
+3%
|
-2.31
-3%
|
-2.56
-11%
|
-2.37
+7%
|
-2.63
-11%
|
-2.97
-13%
|
-3.27
-10%
|
-3.44
-5%
|
-3.45
0%
|
-2.87
+17%
|
-2.62
+9%
|
-2.32
+11%
|
-2.44
-5%
|
-3.15
-29%
|
-3.54
-12%
|
-4
-13%
|
-4.01
0%
|
-3.6
+10%
|
-3.38
+6%
|
-2.43
+28%
|
-1.27
+48%
|
-1.36
-7%
|
-0.93
+32%
|